AL-S Pharma Appoints Internationally Recognized Neurologist and Clinical Trial Expert Prof. Dr. Angela Genge as Chief Medical Officer

AL-S Pharma announced today that it has appointed Angela Genge, MD, Professor of Neurology at McGill University in Montreal, as Chief Medical Officer (CMO). With a distinguished record in amyotrophic lateral sclerosis (ALS) research and the Head of ALS Global Centre of Excellence for Research and Patient Care at McGill, Dr. Genge will join the company’s executive team to further develop AP-101 for the treatment of ALS. Since 2016, Dr. Genge has served as the global principal investigator for the Phase 1 and Phase 2 clinical development of AP-101, a first-in-class investigational antibody targeting misfolded SOD1. The company recently reported positive topline Phase 2 study results of AP-101 for the treatment of ALS (press release Sept 4, 2025).

“We are very happy to welcome Prof. Dr. Genge in an expanded role at this exciting time for AL-S Pharma,” said Michael Salzmann, PhD, Chief Executive Officer of AL-S Pharma. “As an internationally recognized leader in ALS, Prof. Dr. Genge’s expertise will be pivotal to guide our AP-101 late-stage development. Together, we look forward to advancing this potential first-in-class, disease-modifying therapy for ALS

Angela Genge, MD, FRCP, is a recognized leader in ALS clinical research and drug development. She has served as global principal investigator on pivotal ALS trials, advised regulatory authorities, and participated in more than 80 global clinical advisory boards and trial steering committees. Her contributions have been recognized with prestigious awards such as the Forbes Norris Award, the PACTALS Excellent Research Award, and the Wings Over Wall Street Diamond Award.

“AL-S Pharma’s commitment to develop AP-101 as a first-in-class therapy targeting misfolded SOD1, a key driver of disease-progression, has always impressed me,” said Dr. Genge. “I am very much looking forward to working together with the leadership team to further advance the clinical development in an effort to bring this innovative therapy to patients.”

In 2016, Neurimmune and TVM Capital Life Science co-created AL-S Pharma AG to develop AP-101. AL-S Pharma has executed its innovative clinical plan for AP-101 in collaboration with an international network of ALS experts. The company recently completed a global, randomized, double-blind, placebo-controlled Phase 2 study evaluating safety, tolerability, pharmacodynamic markers, and pharmacokinetics of AP-101 in both patients with sporadic ALS (N=52) and patients with mutant SOD1-ALS (N=21) over 24 weeks followed by a 24-week open-label extension and a safety follow-up period. Further information on the clinical study of AP-101 for ALS can be accessed on ClinicalTrials.gov (study number NCT05039099).